


Notice to Comply

Application No.

09/806,125

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)

MATSUTANI ET AL.

Art Unit

1642

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
SR 9/23/04
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216


For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support


Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/806,125E
Source: IFW/b
Date Processed by STIC: 9/14/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04



IFW16

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/806,125E

DATE: 09/14/2004

TIME: 10:03:45

Input Set : A:\PTO.LM.txt

Output Set: N:\CRF4\09142004\I806125E.raw

3 <110> APPLICANT: MATSUTANI, Etsuya
 4 NAITO, Kenichiro
 6 <120> TITLE OF INVENTION: Agents For Retarding Change of Hormone-dependent Cancer into
 Hormone-
 7 independent Cancer
 9 <130> FILE REFERENCE: 2556USOP
 11 <140> CURRENT APPLICATION NUMBER: 09/806,125E
 12 <141> CURRENT FILING DATE: 2001-03-28
 14 <150> PRIOR APPLICATION NUMBER: PCT/JP99/05533
 15 <151> PRIOR FILING DATE: 1999-10-07
 17 <150> PRIOR APPLICATION NUMBER: JP 10-286793
 18 <151> PRIOR FILING DATE: 1998-10-08
 20 <160> NUMBER OF SEQ ID NOS: 13
 22 <170> SOFTWARE: PatentIn version 3.0

Does Not Comply
 Corrected Diskette Needed

ERRORED SEQUENCES

394 <210> SEQ ID NO: 13
 395 <211> LENGTH: 32
 396 <212> TYPE: DNA
 397 <213> ORGANISM: artificial
 399 <220> FEATURE:
 400 <223> OTHER INFORMATION: primer
 402 <400> SEQUENCE: 13
 403 cgtcatactc ctgcttgctg atccacatct gc
 E--> 408 (8)

32

Delete

see p.2 for more error

09/806,125E 2

<210> 1
<211> 10
<212> PRT
<213> artificial

<220>
<223> LH-RH peptide derivative

<220>
<221> MOD_RES
<222> (6)..(6)
<223> (Y) = DLeu, DAla, DTrp, DSer(tBu), D2Nal, or Dhis(ImBzl)

Xaa

<220>
<221> MOD_RES
<222> (10)..(10)
<223> (Z) = Gly-NH2 or -NH-C2H5

Xaa

<400> 1

Pro His Trp Ser Tyr Xaa Leu Arg Pro Xaa
1 5 10

*This error also appears
in subsequent sequences.
FYI: Please ensure that Xaa
represents a single amino
acid.*

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/806,125E

DATE: 09/14/2004
TIME: 10:03:46

Input Set : A:\PTO.LM.txt
Output Set: N:\CRF4\09142004\I806125E.raw

Invalid <213> Response:

- Use of "Artificial" only as "<213> Organism" response is incomplete,
- per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

• Seq#:1,2,3,4,5,6,7,8,9,10,11,12,13

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/806,125E

DATE: 09/14/2004

TIME: 10:03:46

Input Set : A:\PTO.LM.txt

Output Set: N:\CRF4\09142004\I806125E.raw

L:46 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
L:71 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0
L:132 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0
L:188 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
L:224 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0
L:272 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:302 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:344 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0
L:380 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0
L:408 M:254 E: No. of Bases conflict, this line has no nucleotides.